CDP870 studies
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Preliminary data from a Phase III trial examining the pegylated TNF inhibitor in combination with methotrexate in patients with moderate to severe rheumatoid arthritis is positive, Celltech reports. A significant response in the primary endpoint, ACR20, was seen at week one and maintained for the study's six-month duration. A Phase III monotherapy trial is slated to conclude in the third quarter. Celltech plans to commence the remainder of the Phase III program in the second half of 2004. Pfizer had decided to delay initiation of further Phase III studies until results from the RA studies were seen. Phase III trials in Crohn's disease are ongoing, with submission planned for 2005...
You may also be interested in...
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.